What is Codexis?
Codexis, Inc., incorporated in 2002 and publicly traded as CDXS on NASDAQ, is a leader in enzyme engineering, headquartered in Redwood City, California. The company utilizes its proprietary CodeEvolver protein engineering technology to discover, develop, and enhance high-performance enzymes and proteins. These innovations are critical for improving manufacturing yields, reducing waste, and increasing efficiency in the production of small molecule pharmaceuticals and nucleic acid-based medicines. Codexis is also advancing its ECO Synthesis platform for the scalable, enzymatic manufacturing of RNAi therapeutics, serving diverse industries including pharmaceuticals, biotherapeutics, food and beverage, and fine chemicals. Their commitment to sustainable manufacturing has been recognized with the Presidential Green Chemistry Challenge Award.
How much funding has Codexis raised?
Codexis has raised a total of $160M across 4 funding rounds:
Series D
$37M
Stock Offering
$78M
Stock Offering
$5M
Debt
$40M
Series D (2006): $37M with participation from Pequot Ventures, CMEA Ventures, Maxygen, Chevron, and Bio*One Capital
Stock Issuance/Offering (2010): $78M, investors not publicly disclosed
Stock Issuance/Offering (2019): $5M supported by Casdin Capital
Debt (2024): $40M featuring Innovatus Capital Partners
Key Investors in Codexis
Pequot Ventures
Pequot Ventures, now known as FirstMark Capital, is a venture capital firm that operates in the Information & Document Management industry, often investing in early-stage technology companies.
CMEA Ventures
CMEA Capital is a venture capital firm with a strong focus on life sciences and high technology, investing in science-based companies with differentiated technology and experienced teams.
Innovatus Capital Partners
Innovatus Capital Partners specializes in long-term capital investments, focusing on asset-based opportunities and areas where value is misunderstood or mispriced, particularly in complex market conditions.
What's next for Codexis?
With the recent major strategic investment, Codexis is poised to accelerate its development of advanced enzymatic solutions, particularly its ECO Synthesis platform for RNAi therapeutics. This funding is expected to fuel further research and development, expand manufacturing capabilities, and strengthen its market presence in the biopharmaceutical and fine chemical industries. The company's focus on sustainable and efficient manufacturing processes aligns with growing industry demands for greener chemical production, positioning Codexis for continued growth and innovation in enzyme engineering.
See full Codexis company page
